Brainstorm Cell (NASDAQ:BCLI) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.20) by 15 percent. This is a 32 percent increase over losses of $(0.25) per share from the same period last year.
There’s ‘Outsized’ Risk-Reward For This Biotech, Morgan Stanley Says, Predicting Shares Could Grow More Than 30%
Morgan Stanley has assumed coverage on Ionis Pharmaceuticals Inc (NASDAQ:IONS) with an Overweight (previously Underweight) rating and a price target of $57 from…
